CXCL1 and Stroke: In the same vein, JAK3 inhibition with 10 mg/kg decernotinib did not affect stroke-induced upregulation of Ccl2, Cxcl10, and Cxcl1, chemokines important for immune cell trafficking, nor proinflammatory mediators IL-1β, IL-6, Tnfα, Ptgs2, and Mmp-9 that exacerbate stroke damage.